The cluster of insider buying, especially the $13M purchase by the largest shareholder and the CEO's concurrent buy, is a strong bullish signal. Traders should watch for further enrollment updates on the NANOPULSE-AF trial and potential partnership or financing announcements as cash burn continues. The cross-filing context (earnings + insider cluster) is an AMPLIFIER per actuarial data, supporting elevated impact.
Price Chart
Executive Summary
Two insiders at Pulse Biosciences, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market purchases totaling $13.3M on May 11, 2026, following the company's Q1 earnings release on May 4. The purchases represent ~0.7% of the $1.9B market cap, a significant insider vote of confidence that aligns with the positive clinical catalyst from the accelerated NANOPULSE-AF trial timeline.
Key Financial Metrics
Key Facts
- CEO Paul LaViolette purchased 15,000 shares for $295K on May 11, 2026.
- Director/10% owner Robert Duggan purchased 660,233 shares for $13.0M on May 11, 2026.
- Total insider buying of $13.3M represents ~0.7% of the $1.9B market cap.
- Purchases occurred 7 days after Q1 2026 earnings (May 4) which showed a narrower-than-expected GAAP net loss of $18.6M (-$0.27 EPS, beat by $0.05).
- The pivotal NANOPULSE-AF cardiac catheter trial enrollment was accelerated to early Q4 2026, a key clinical catalyst.
- Recent insider activity (30d) totals $26.6M in buys, indicating sustained insider conviction.
Financial Impact
Insider purchases of $13.3M (0.7% of market cap) signal strong conviction; Q1 net loss of $18.6M was better than consensus by $0.05 EPS.
Risk Factors
- Revenue remains negligible at $0.4M; the company is pre-commercial and burning cash.
- Clinical trial execution risk — NANOPULSE-AF enrollment acceleration could face delays.
- Dilution risk from potential future equity offerings to fund operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PLSE-1778887571675 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $46.32 | awaiting T+60 | — | $53.00 (+14.42%) |
Oct 7, 2026 20d ago | 8-K | $49.09 | awaiting T+60 | — | $53.00 (+7.96%) |
Sep 15, 2026 6w ago | 8-K | $55.20 | awaiting T+60 | — | $53.00 (−3.99%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $53.00 (−24.97%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $53.00 (−24.97%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $53.00 (+54.74%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $53.00 (+117.48%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $53.00 (+112.08%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $53.00 (+106.95%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $53.00 (+177.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers